首页> 美国卫生研究院文献>Cancer Biotherapy Radiopharmaceuticals >In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells
【2h】

In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells

机译:对小鼠胃泌素释放肽和神经肽Y1受体具有强亲和力的异双价双靶探针的体外小鼠和人血清稳定性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Receptor-targeting radiolabeled molecular probes with high affinity and specificity are useful in studying and monitoring biological processes and responses. Dual- or multiple-targeting probes, using radiolabeled metal chelates conjugated to peptides, have potential advantages over single-targeting probes as they can recognize multiple targets leading to better sensitivity for imaging and radiotherapy when target heterogeneity is present. Two natural hormone peptide receptors, gastrin-releasing peptide (GRP) and Y1, are specifically interesting as their expression is upregulated in most breast and prostate cancers. One of our goals has been to develop a dual-target probe that can bind both GRP and Y1 receptors. Consequently, a heterobivalent dual-target probe, t-BBN/BVD15-DO3A (where a GRP targeting ligand J-G-Abz4-QWAVGHLM-NH2 and Y1 targeting ligand INP-K [ɛ-J-(α-DO3A-ɛ-DGa)-K] YRLRY-NH2 were coupled), that recognizes both GRP and Y1 receptors was synthesized, purified, and characterized in the past. Competitive displacement cell binding assay studies with the probe demonstrated strong affinity (IC50 values given in parentheses) for GRP receptors in T-47D cells (18 ± 0.7 nM) and for Y1 receptors in MCF7 cells (80 ± 11 nM). As a further evaluation of the heterobivalent dual-target probe t-BBN/BVD15-DO3A, the objective of this study was to determine its mouse and human serum stability at 37°C. The in vitro metabolic degradation of the dual-target probe in mouse and human serum was studied by using a 153Gd-labeled t-BBN/BVD15-DO3A and a high-performance liquid chromatography/radioisotope detector analytical method. The half-life (t1/2) of degradation of the dual-target probe in mouse serum was calculated as 7 hours and only ∼20% degradation was seen after 6 hours incubation in human serum. The slow in vitro metabolic degradation of the dual-target probe can be compared with the degradation t1/2 of the corresponding monomeric probes, BVD15-DO3A and AMBA: 15, and ∼40 minutes for BVD15-DO3A and 3.1 and 38.8 hours for AMBA in mouse and human serum, respectively. A possible pathway for in vitro metabolic degradation of the t-BBN/BVD15-DO3A in mouse serum is proposed based on the chromatographic retention times of the intact probe and its degradants.
机译:具有高亲和力和特异性的靶向受体的放射性标记分子探针可用于研究和监测生物学过程和反应。使用与肽结合的放射性标记金属螯合物的双靶或多靶探针比单靶探针具有潜在的优势,因为当存在靶异质性时,它们可以识别多个靶,从而导致成像和放射治疗的敏感性更高。两种天然激素肽受体,即胃泌素释放肽(GRP)和Y1,特别令人感兴趣,因为它们的表达在大多数乳腺癌和前列腺癌中均上调。我们的目标之一是开发一种可同时结合GRP和Y1受体的双靶探针。因此,使用异双价双靶探针t-BBN / BVD15-DO3A(其中GRP靶向配体JG-Abz4-QWAVGHLM-NH2和Y1靶向配体INP-K [ɛ-J-(α-DO3A-ɛ-DGa) -K] YRLRY-NH2偶联),该识别过去识别,合成和纯化了识别GRP和Y1受体。用探针进行的竞争性置换细胞结合试验研究表明,它对T-47D细胞中的GRP受体(18±±0.7 nM)和MCF7细胞中的Y1受体(80±±11 nM)具有很强的亲和力(括号中给出的IC50值)。作为对异双价双靶探针t-BBN / BVD15-DO3A的进一步评估,本研究的目的是确定其在37°C时的小鼠和人血清稳定性。使用 153 Gd标记的t-BBN / BVD15-DO3A和高效液相色谱/放射性同位素检测器分析研究双靶探针在小鼠和人血清中的体外代谢降解方法。计算双靶探针在小鼠血清中的降解半衰期(t1 / 2)为7小时,在人血清中孵育6小时后仅观察到约20%的降解。可将双靶探针的缓慢体外代谢降解与相应的单体探针BVD15-DO3A和AMBA的降解t1 / 2进行比较:BVD15-DO3A为15分钟,约40分钟; AMBA为3.1和38.8小时分别在小鼠和人血清中。根据完整探针及其降解产物的色谱保留时间,提出了小鼠血清中t-BBN / BVD15-DO3A体外代谢降解的可能途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号